MedPath

Intranasal Cocaine and Temperature Regulation During Exercise

Phase 1
Completed
Conditions
Hyperthermia
Exercise
Cocaine Use
Interventions
Registration Number
NCT05809453
Lead Sponsor
University of Texas Southwestern Medical Center
Brief Summary

Assess the effects of intranasal cocaine on temperature regulation and whole-body sweat rate during exercise in warm environmental conditions.

Detailed Description

Previously it was shown that intranasal cocaine attenuates skin blood flow and sweating responses during passive heat stress, when compared to placebo. However, nothing is known about the effects of cocaine on whole-body temperature regulation during mild to moderate exercise in warm environmental condition.

This project will test the hypothesis that intranasal cocaine attenuates whole-body sweat rate, resulting in greater elevations in core temperature during mild to moderate exercise in warm environmental conditions.

Primary data include core temperature, skin temperatures, and whole body sweat rate. Secondary variables include cardiovascular responses, perceptions of exercise exertion and thermal comfort, and metabolic heat production. Intranasal lidocaine will be used as the placebo for cocaine. The selection of the drug administered during the first experimental trial will be randomized, with the other drug administered during the second experimental trial.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
27
Inclusion Criteria
  • 18 to 50 years of age
  • Healthy
  • Body mass index less than 31 kg/m^2
  • Speak English
  • Systolic blood pressure <140 mmHg
  • Diastolic blood pressure <90 mmHg
Exclusion Criteria
  • Subjects not in the defined age range
  • Participants who have cardiac, respiratory, neurological, and/or metabolic illnesses
  • Any known history of renal or hepatic insufficiency/disease
  • Pregnancy or breast feeding
  • Body mass less than 60 kilograms
  • Current smokers, as well as individuals who regularly smoked within the past 3 years
  • Individuals with a history of drug abuse within the past 5 years
  • Individuals who have an unexplained positive urine drug screen (e.g., some agents cause false-positive results and when agent abstained the drug screen is negative, one example could be an over the counter supplement)
  • Currently taking pain modifying medications

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Hot-HumidCocaineParticipants will complete the trial in environmental conditions 38 degrees Celsius with 40% humidity.
Hot-HumidLidocaineParticipants will complete the trial in environmental conditions 38 degrees Celsius with 40% humidity.
Hot-DryCocaineParticipants will complete the trial in environmental conditions 41 degrees Celsius with 15% humidity.
Hot-DryLidocaineParticipants will complete the trial in environmental conditions 41 degrees Celsius with 15% humidity.
Primary Outcome Measures
NameTimeMethod
Change in Core TemperatureCore temperature is measured at baseline and at 60 minutes of heat exposure.

Core temperature will be measured either from a temperature sensor pill or from a rectal temperature probe.

Secondary Outcome Measures
NameTimeMethod
End Skin TemperatureMeasured at the end of heat exposure, 90 minutes from cocaine/lidocaine administration

Skin temperature will be measured from small temperature sensitive electrodes attached to the participant's skin

End Heart RateMeasured at the end of heat exposure, 90 minutes from Cocaine/ lidocaine administration

Heart rate will be measured from ECG electrodes attached to the participant

Whole Body Sweat RateWithin 30 minutes before exposure to warm environmental conditions (before cocaine/ lidocaine administration) and immediately after the heat exposure (90 minutes post cocaine/ lidocaine administration)

Whole body sweat rate is calculated by subtracting the participants post-heat exposure nude body weight from their pre-heat exposure nude body weight

End Mean Arterial PressureMeasured at the end of heat exposure, 90 minutes from cocaine/ lidocaine administration

Systolic and diastolic blood pressure will be measured from a cuff placed on the upper arm.

End Thermal SensationThese values will be obtained at end of the 60 minute heat exposure (90 minutes post cocaine/ lidocaine administration)

Subjective assessment of how hot the subject feels.

Title of Scale: Thermal Sensation Scale; Minimum value: -50 "unbearably cold"; Maximum value: 50: "unbearably hot" Scale presents numbers in increments of 5

Trial Locations

Locations (1)

University of Texas Southwestern Medical Center

🇺🇸

Dallas, Texas, United States

University of Texas Southwestern Medical Center
🇺🇸Dallas, Texas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.